With the Trump administration scaling back federal efforts to protect Americans from medical bills they can’t pay, advocates for patients and consumers have shifted their work to contain the nation’s medical debt problem to state Capitols. Despite progress in some mostly blue states this year, however, recent setbacks in more conservative legislatures underscore the persistent…
Taking a page from the private insurance industry’s playbook, the Trump administration will launch a program next year to find out how much money an artificial intelligence algorithm could save the federal government by denying care to Medicare patients. The pilot program, designed to weed out wasteful, “low-value” services, amounts to a federal expansion of…
AmplifyMD raised a $20 million Series B round for its AI-driven virtual specialty care platform and physician network. Memorial Hermann Health System, both a customer and investor, uses the platform to fill specialty gaps and improve workflows. The post AmplifyMD Snags $20M to Help Hospitals Scale Virtual Specialty Care appeared first on MedCity News.
A new WTW survey reveals that over half of employers exceeded their healthcare budgets in 2024 and expect rising costs to continue, prompting a shift toward cost-containment strategies, vendor accountability, AI adoption and alternative plan designs. The post WTW: Half of Employers Exceeded Their Healthcare Budgets in 2024 appeared first on MedCity News.
A new CDC report highlights a dramatic increase in a dangerous type of drug-resistant bacteria
CDC report finds that cases of newborn syphilis increased by nearly 2 percent compared to 2023
CDC report finds that cases of newborn syphilis increased by nearly 2 percent compared to 2023
This brief analyzes changes in the new tax and budget reconciliation law that modify which drugs will be selected for Medicare drug price negotiation, which will lead to higher Medicare spending and higher costs for beneficiaries who take these medications.
UniQure plans a first quarter 2026 FDA submission for AMT-130 as a treatment for Huntington’s disease. This gene therapy delivers microRNA designed to silence the mutated gene that produces a protein driving this disorder, which so far has no FDA-approved therapies. The post UniQure Gene Therapy’s Clinical Trial Results Keep It on Path to Become…
With recent federal actions to curtail vaccine access, many states have announced actions intended to maintain broader access. This issue brief provides a snapshot of this rapidly changing landscape, tracking which states have instituted changes in response to or in anticipation of administration policy changes.